Welcome to Annexin's IR pages

Annexin Pharmaceuticals AB (publ) was founded in 2014 and is a world-leading biotechnology company in the Annexin A5 area, for the treatment of various diseases that involve damage and inflammation in the blood vessels.


IR contact:


Anders Haegerstrand, CEO


+46 70 575 50 37


Susanne Andersson, Chief Financial Officer


+46 730 668 904